Buys
Open market- Shares
- Avg price
- Total value
Erick Gamelin - Chief Development Officer at Acrivon Therapeutics, Inc.
Issuer-level insider activity
- Role
- Chief Development Officer
- Issuer ticker
- ACRV on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for Erick Gamelin in Acrivon Therapeutics, Inc.
Sells
Open market- Shares
- -400
- Avg price
- $2.01
- Total value
- -$804
Net
Past year- Shares
- -400
- Share %
- -100%
- Total value
- -$804
Reported holdings for Erick Gamelin in Acrivon Therapeutics, Inc.
Form 4 holding
Chief Development Officer
Acrivon Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 52,592
- Estimated value
- $105,709
- Report date
- 18 Aug 2026
- Price
- $2.01
- Ownership
- Direct
Form 4 holding
Chief Development Officer
Acrivon Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 94,946
- Estimated value
- Report date
- 01 Mar 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Erick Gamelin in Acrivon Therapeutics, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.